# US 2005/0233444 A1 · System and method for forming a non-ablative cardiac conduction block

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233444 A1
- Document ID: US20050233444A1
- Status: Published application
- Kind: A1
- Application number: 11/142,180
- Filed: 2005-05-31
- Published: 2005-10-20
- Earliest claimed: 2003-01-21
- Inventors: Randall Lee
- Web page: https://patentgrep.com/patent/US20050233444A1

## CPC

- A61M 25/0026: {Multi-lumen catheters with stationary elements (catheter assemblies comprising a catheter in combination with a guide tube, sheath or sleeve A61M2025/0681; catheters comprising telescoping coaxial elements A61M2025/0175)}
- A61B 5/283: Invasive
- A61B 5/6852: {Catheters}
- A61B 17/00491: {Surgical glue applicators}
- A61M 25/0084: {being one or more injection needles}
- A61B 2017/00044: {Sensing electrocardiography, i.e. ECG}
- A61B 2017/00243: {cardiac}
- A61B 2017/00323: {Cables or rods}
- A61B 2017/00495: {for two-component glue}
- A61M 25/0147: {with movable mechanical means, e.g. pull wires}
- A61M 2025/0085: {Multiple injection needles protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip}
- A61M 2025/0089: {Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M 2025/1086: {having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A system forms a cardiac conduction block at a location in a heart of a patient without substantially ablating cardiac tissue. The system includes a delivery system coupled to a source of material that is substantially non-ablative with respect to cardiac tissue. The delivery system delivers the material to the location, and the material at the location forms a conduction block without ablating the cardiac cells there. The material may include living cells, such as for example skeletal myocytes, and/or may include a non-living matter such as biopolymers such as a fibrin glue agent, or collagen agents. An expandable member with needle assembly is used to deliver the material so as to form a non-ablative circumferential conduction block at a location where a pulmonary vein extends from an atrium.

## Claims

### Claim 1

A system for treating a cardiac arrhythmia in a heart of a patient, comprising:
a delivery system; and
a source of material coupled to the delivery system;
wherein the delivery system is adapted to deliver a volume of the material from the source to a location associated with the patient's heart that includes cardiac cells;
wherein the material is substantially non-ablative with respect to cardiac cells; and
wherein the material is adapted to form a substantially non-ablative conduction block at the location; and
wherein the material comprises a collagen agent.

### Claim 2 (depends on 1)

The system of claim 1, wherein the material further comprises living cells.

### Claim 3 (depends on 2)

The system of claim 2, wherein the living cells comprise myocytes.

### Claim 4 (depends on 1)

The system of claim 1, wherein the material further comprises a non-living material.

### Claim 5 (depends on 4)

The system of claim 4, wherein the material further comprises a polymer agent.

### Claim 6 (depends on 5)

The system of claim 5, wherein the polymer agent comprises a fibrin glue agent.

### Claim at position 7

7-9. (canceled)

### Claim 10 (depends on 1)

The system of claim 1, wherein the material is adapted to be delivered into extracellular matrix between cardiac cells at the location.

### Claim 11 (depends on 10)

The system of claim 10, wherein the material is adapted to interfere with gap-junctions between cardiac cells at the location.

### Claim 12 (depends on 1)

The system of claim 1, wherein:
the delivery system is adapted to deliver the material to the location along a ventricle wall of a ventricle in the patient's heart.

### Claim 13 (depends on 1)

The system of claim 1, wherein:
the delivery system is adapted to deliver the material to the location along an atrial wall of an atrium in the patient's heart.

### Claim 14 (depends on 1)

The system of claim 1, wherein:
the delivery system is adapted to deliver the material to the location where a pulmonary vein extends from an atrium in the patient's heart.

### Claim at position 13

15-19. (canceled)

### Claim 20 (depends on 1)

The system of claim 1, wherein the material comprises:
a first material that comprises living cells; and
a second material that is non-living and that is adapted to enhance formation of the conduction block.

### Claim 21 (depends on 20)

The system of claim 20, wherein the second material comprises a polymer agent.

### Claim 22 (depends on 21)

The system of claim 21, wherein the polymer agent comprises a fibrin glue agent.

### Claim 23 (depends on 20)

The system of claim 20, wherein the second material is adapted to enhance retention of the living cells at the location.

### Claim 24 (depends on 20)

The system of claim 20, wherein the second material is adapted to intervene at gap-junctions between adjacent cells at the location.

### Claim 25

(canceled)

### Claim 26

A method for treating a cardiac arrhythmia in a heart of a patient, comprising:
providing a material that comprises a collagen agent; and
forming a conduction block at a location associated with the patient's heart that includes cardiac cells by delivering the material to the location and without substantially ablating cardiac cells, wherein the material being delivered to the region comprises a non-living material.

### Claim at position 21

27-34. (canceled)

### Claim 35

A system for treating a cardiac arrhythmia in a heart of a patient, comprising:
a delivery system; and
an injectable collagen agent coupled to the delivery system;
wherein the delivery system is adapted to deliver the injectable collagen agent to a location associated with the patient's heart that includes cardiac cells; and
wherein the delivery system is not coupled to a source of living cells.

### Claim 36 (depends on 35)

The system of claim 35, wherein the delivery system is adapted to provide intracardiac delivery of the injectable collagen agent to the location via at least one of the cardiac chambers.

### Claim 37 (depends on 35)

The system of claim 35, wherein the injectable collagen agent comprises collagen.

### Claim 38 (depends on 35)

The system of claim 35, wherein the injectable collagen agent comprises:
at least one precursor material; and
wherein the at least one precursor material when delivered to the location is adapted to form collagen.

### Claim 39 (depends on 38)

The system of claim 38, wherein the delivery system is adapted to mix the collagen agent with another agent before delivering the collagen agent to the location.

### Claim 40 (depends on 35)

The system of claim 35, wherein the delivery system is adapted to deliver the collagen agent to the location and another agent to the location separately such that they mix at the location.

### Claim 41 (depends on 35)

The system of claim 35, wherein the delivery system comprises at least one needle.

### Claim 42 (depends on 35)

The system of claim 35, wherein the delivery system comprises:
a catheter having an elongate body with a proximal end portion, a distal end portion, and at least one lumen extending between a proximal port located along the proximal end portion and a distal port located along the distal end portion; and
wherein the proximal port is adapted to couple to a source that contains at least a part of the injectable collagen agent.

### Claim 43

(canceled)

### Claim 44

A method for treating a medical condition associated with a heart of a patient, comprising:
injecting an injectable material that comprises a collagen agent into a region of cardiac tissue within the heart of the patient in a manner such that the injected collagen agent provides a primary therapeutic effect to the heart.

### Claim 45 (depends on 44)

The method of claim 44, further comprising:
injecting the injectable collagen agent into the region of cardiac tissue without delivering living cells into the region.

### Claim 46 (depends on 44)

The method of claim 44, wherein the injectable collagen agent being delivered into the region comprises collagen.

### Claim 47 (depends on 44)

The method of claim 44, further comprising:
forming a polymerized fibrin glue in-vivo by mixing a first precursor material and a second precursor material within the patient's body.

### Claim 48 (depends on 44)

The method of claim 44, further comprising:
injecting the injectable collagen agent into the location from within a cardiac chamber of the patient's heart.

### Claim 49 (depends on 44)

The method of claim 44, further comprising:
injecting the injectable collagen agent along a predetermined pattern at the location that is adapted to provide the primary therapeutic effect to the heart with the injected collagen agent.
